[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"idiopathic-pulmonary-fibrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:idiopathic-pulmonary-fibrosis":578},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,59,0,25,[9,46,75,104,131,142,167,186,197,221,241,259,288,314,332,351,377,398,417,443,462,485,503,524,557],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053519",false,"NCT07284459","Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis","Key Inclusion Criteria:\n\n* Male or female ≥ 40 years of age at the time of Randomization.\n* A diagnosis of IPF within 7 years prior to Screening, based on the 2022 ATS\u002FERS\u002FJRS\u002FALAT practice guideline as confirmed by the Investigator, and a centrally read screening HRCT consistent with usual interstitial pneumonia (UIP) or probable UIP.\n* Percent predicted (pp) FVC ≥ 40% on Screening spirometry.\n* Participants may enter the study whether or not they are receiving background nintedanib or pirfenidone therapy approved for the treatment of IPF, but not both concurrently.\n\nKey Exclusion Criteria:\n\n* Those with a history of interstitial lung disease (ILD) other than IPF are not eligible.\n* Those with pulmonary arterial hypertension (PAH) requiring multi-drug therapy are not eligible.\n* Those who have experienced an IPF exacerbation within 6 weeks of Screening, or during Screening, are not eligible.\n* Those with an estimated glomerular filtration rate (eGFR) ≤ 30 ml\u002Fmin\u002F1.73 m2 (Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] formula) (Inker 2021) or who have Child-Pugh Class B or C hepatic impairment are not eligible.\n* Female participants must not be of childbearing potential.\n\nAdditional inclusion and exclusion criteria apply.","ALL","40 Years",{"count":19,"type":20},324,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.",[26],"Idiopathic Pulmonary Fibrosis",[26,28,29,30,31,32],"PIPE 791","Pulmonary Fibrosis","IPF","ILD","Interstitial lung disease","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-01-08",{"date":41,"type":20},"2028-06",{"name":43,"class":44},"Contineum Therapeutics","INDUSTRY",49,{"id":47,"slug":4,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100053230","NCT07679893","Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis","A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial of the Efficacy and Safety of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis Followed by an Open-Label Extension","INFLO-2","Inclusion Criteria:\n\n* 40-80 years old when signing consent and entering screening.\n* Diagnosed with IPF based on current ATS\u002FERS\u002FJRS\u002FALAT guidelines.\n* Either new to treatment or on a stable dose of pirfenidone and\u002For nerandomilast for at least 3 months before screening.\n* Weighs more than 40 kg (88 lb) at screening.\n* Women who can become pregnant:\n* Must have a negative pregnancy test at screening.\n* Must use an approved birth control method from screening until at least 1 month after the last study dose.\n* Men who can father a child and are sexually active with women who can become pregnant:\n* Must use an approved birth control method during treatment and for at least 3 months after the last study dose.\n* Must not donate sperm during treatment and for at least 3 months after the last study dose.\n* Willing to follow all study rules and restrictions.\n* Willing and able to attend study visits and complete study procedures.\n* Able to perform spirometry (lung function testing) as required by the study.\n\nExclusion Criteria:\n\n* Has a lung disease caused by something other than IPF.\n* Has a connective tissue or autoimmune disease (such as lupus, scleroderma, or rheumatoid arthritis).\n* Has another condition that significantly affects breathing.\n* Has serious heart or blood vessel disease.\n* Has a recent or current infection.\n* Was recently hospitalized for COVID-19, an IPF flare-up, or a lung infection.\n* Has a history of asthma (except childhood asthma that has resolved).\n* Has another medical condition or abnormal test result that may affect study participation or safety.\n* Cannot perform high-quality spirometry testing.\n* Has obstructive lung disease.\n* Has abnormal liver function tests.\n* Has moderate to severe liver disease.\n* Has severe kidney disease.\n* Has recently used high-dose steroids or other immune-suppressing medications.\n* Has active cancer or recent cancer treatment.\n* Is on, or expected to be added to, a transplant list.\n* Had major surgery recently or has planned procedures that could interfere with the study.\n* Has had a severe reaction to nintedanib or cannot take nintedanib safely.\n* Has recently used certain medications that may interact with the study drug.\n* Is currently using, or plans to use, prohibited medications during the study.\n* Has recently participated in another clinical trial.\n* Has current alcohol or drug abuse issues.\n* Donated a significant amount of blood recently.\n* Received a live vaccine recently.\n* Currently smokes, recently smoked, or quit smoking less than 1 year ago.\n* Requires more than 6 L\u002Fmin of oxygen while at rest.","80 Years",{"count":55,"type":20},210,[23],"This trial is a randomized, double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of inhaled Nintedanib Dry Powder Inhalation (DPI) in adults with idiopathic pulmonary fibrosis (IPF). Participants are randomized to receive either 2 mg QID, 4 mg BID, or matching placebo for 12 weeks, followed by a 24-week open-label extension in which all participants receive active treatment. The primary focus is on safety-particularly bronchospasm events, lung function changes (FEV1, FEV1\u002FFVC), and adverse event rates and assessing the effectiveness of nintedanib DPI in treating IPF.",[26,59],"Idiopathic Pulmonary Fibrosis (IPF)",[61,62,63,64,65],"inhalable treatments","lung scarring","Pulmonary fibrosis","fibrosis","pulmonary","2026-07-09",{"date":36,"type":37},{"date":69,"type":20},"2026-06-30",{"date":71,"type":20},"2028-12",{"name":73,"class":44},"Mannkind Corporation",2,{"id":76,"slug":4,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100541118","NCT06325696","H01 in Adults With Interstitial Lung Disease (The SOLIS Study)","Phase IIa Investigation of H01 in Adults With Interstitial Lung Disease (The SOLIS Study)","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Ability of subject to understand, and the willingness to sign a written informed consent document and comply with requirements of the study\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or Female participants ages \\>18 years\n* MD diagnosis of Idiopathic Pulmonary Fibrosis or other progressive ILD as defined previously\n* DLCO\\>30% and FVC\\>45%\n* Subjects in reproductive age who are heterosexually active must use an acceptable method of contraception: condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, IUD, or Hormone-based contraceptive\n* Agreement to adhere to Lifestyle Considerations throughout study duration\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Active on lung transplantation list\n* On supplemental oxygen at rest\n* Evidence of an acute respiratory infection or exacerbation of pulmonary fibrosis\n* Known diagnosis of celiac disease or wheat or gluten allergies\n* Cirrhosis or active viral or non-viral hepatitis: Bilirubin, AST and ALT values higher than twice the upper range of normal, or a Child-Pugh score of 7 or more\n* Subjects with history of active Inflammatory Bowel Disease, dysphagia, achalasia, or difficulty swallowing capsules, tablets or pills\n* Subjects with significant renal impairment defined as eGFR lower than 40 ml\u002Fmin.\n* Subjects with a baseline corrected Fridericia's QT interval (QTcF) \\>450ms or baseline ECG abnormalities which, in the opinion of the study physician, are clinically significant and would place the participant at increased risk for adverse effects.\n* Subjects with ongoing alcohol or illegal drug use disorder\n* Subjects who are pregnant, lactating or attempting to conceive\n\n  * Participants able to become pregnant (have not completed menopause, had a hysterectomy and\u002For both tubes and\u002For both ovaries removed) must use effective birth control methods to try and not become pregnant while participant in this study. Methods include (a) partner vasectomy, (b) bilateral tubal ligation, (c) intrauterine devices (IUDs), (d) hormonal implants (such as Implanon), or (e) other hormonal methods (birth control pills, injections, patches, vaginal rings).\n  * Male participants able to father children with a partner able to become pregnant must agree to use effective birth control (listed above) to participate in this study.\n* Known allergy to hymecromone or any component thereof\n* Chronic therapy with medications that are known potent human UDP-glucuronosyltransferase inhibitors: canagliflozin, temazepam, tacrolimus.\n* Physician concern that participant may not adhere to the study protocol\n* Current participation in another clinical treatment trial for ILD. May participate after 12 weeks from conclusion of another treatment trial.\n* Changing dose of other ILD medications over the 3 months prior to baseline\n* Any condition(s) or diagnosis, both physical or psychological, or physical exam finding that place the participant at increased risk for adverse effects, as determined by the study physician.","18 Years","100 Years",{"count":84,"type":20},37,[23],"Background:\n\nInterstitial lung disease affects the tissues that aid the transfer of oxygen and carbon dioxide between the air and the bloodstream. The disease can cause fibrosis, a thickening and scarring of lung tissue. Fibrosis often continues getting worse, and most people with this disease die in 3 to 5 years.\n\nObjective:\n\nTo test a study drug (hymecromone) in people with interstitial lung disease or lung fibrosis.\n\nEligibility:\n\nPeople aged 18 years and older with interstitial lung disease or lung fibrosis.\n\nDesign:\n\nParticipants will have at least 7 clinic visits over 5 months.\n\nParticipants will have screening and baseline visits. They will have blood tests and tests of their heart function. They will give a sputum sample. Other tests will include:\n\nSpirometry: Participants will breathe in and out through a mouthpiece to measure how much air they can hold in their lungs and how hard they can breathe.\n\nDiffusion capacity of lungs for carbon monoxide: Participants will breathe in a gas that contains a small amount of carbon monoxide. Then they will breathe through a mouthpiece. This test measures how well oxygen moves from the air into the blood.\n\nResting energy expenditure. Participants will lie still for 30 minutes with a clear dome over their head. This test measures the calories their body burns at rest.\n\n6-minute walk test. Participants will walk at their normal pace for 6 minutes. Their vital signs and blood oxygen levels will be checked.\n\nHymecromone is a tablet taken by mouth. Participants will take 2 tablets every morning and 2 tablets every night for 12 weeks. Tests will be repeated at study visits.",[88,26,89],"Interstitial Lung Disease","Lung Diseases, Interstitial",[29,91,92,93],"Lung disease","Hyaluronan","Drug",{"date":95,"type":37},"2026-07-01",{"date":97,"type":37},"2025-05-05",{"date":99,"type":20},"2027-12-31",{"name":101,"class":102},"National Institute of Environmental Health Sciences (NIEHS)","NIH",1,{"id":105,"slug":4,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":130},"100644927","NCT07674745","Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis","Study of Therapeutic Plasma Exchange, Rituximab, and Intravenous Immunoglobulin for Progressive Idiopathic Pulmonary Fibrosis (STRIVE II)","STRIVE II","Inclusion Criteria:\n\n1. Age between 40-85 years old.\n2. A diagnosis of IPF that fulfills latest ATS\u002FERS Consensus Criteria.\n3. A diagnosis of Progressive IPF (P-IPF), defined as a relative decrease of FVC%p \\>10% during the preceding twelve months, and substantiated by replicate values at least three weeks apart.\n4. Ability and willingness to give informed consent (no surrogates) and adhere to requirements.\n5. Have eligibility confirmed by a consensus of trial investigators.\n6. Is not now or has been in experimental regimen for at least 2 weeks (or 5 half-lives of agent) and agrees to not become participants in other experimental regimens (other than solely observational registries) for the duration of their participation in this trial (180 days).\n7. Has been immunized with 2025-2026 COVID-19 vaccine (and later versions as they become available) between 1 and 26 weeks prior to randomization.\n8. IPF duration \\\u003C10 years, based on the date of definitive diagnosis.\n9. Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1\u002FFVC) \\>0.70\n\nExclusion Criteria:\n\n1. Diagnoses of current infection by clinical or microbial assessments.\n2. Diagnoses of an additional or alternative etiology for lung dysfunction based upon clinical assessment, including sepsis, congestive heart failure, thromboembolism, worsened pulmonary artery hypertension, etc. using routine clinical evaluations under direction of the attending physician.\n3. History or serologic evidence of hepatitis B or C infection. Positive serology for Hepatitis C will not exclude patients if their circulating HC virus RNA test is negative.\n4. Coagulopathy, defined as an INR \\>1.6, PTT \\>2x control, fibrinogen \\\u003C100 mg\u002FdL, or platelet count \\\u003C50,000 unless these abnormalities can be reversed.\n5. Uncontrolled diabetes or hypertension (systolic BP \\>160 mm Hg and diastolic BP \\>100 mm Hg) that would contraindicate use of corticosteroids.\n6. Hemodynamic instability, defined as an inotrope or vasopressor requirement.\n7. History of reactions to blood products, murine-derived products, or prior rituximab use within the last six months.\n8. History of malignancy, excluding basal or squamous cell skin cancer and low-risk prostate cancer, the latter defined as stage T1 or T2a, with prostate specific antigen \\\u003C10 ng\u002Fdl. AART is not known to promote cancer, and these criteria are within current guidelines.\n9. Unwillingness to accept blood product transfusion.\n10. Diagnosis of major comorbidities expected to interfere with study participation.\n11. Treatment for \\>14 days within the preceding month with \\>20 mg. prednisone (or equivalent) or any treatment during the last month with a cellular immuno-suppressant (e.g., cyclophosphamide, methotrexate, calcineurin inhibitors, etc.), or with rituximab (or other anti-B-cell biological agents) within the last 6 months.\n12. Current treatment with an angiotensin converting enzyme inhibitor that cannot be discontinued and\u002For substituted (to obviate hemodynamic lability during TPE).\n13. Fertile women who do not agree to contraception or abstinence. IPF is a disease of older adults, and male predominant, so this will not be a frequent consideration.\n14. An alternative, concordant or historical diagnosis of interstitial lung diseases other than IPF, including idiopathic fibrosis with autoimmune features (IPAF) per clinical domain.1\n15. IgA deficiency, to preclude IVIg reactions.\n16. Listed with the United Network for Organ Sharing (UNOS) for lung transplant at the time of enrollment, to minimize the number of censoring due to very early transplants.\n17. Ongoing suspected or known acute exacerbations of IPF (AE-IPF), defined as new onset (within the last 30 days) of dyspnea with increased hypoxemia or oxygen requirement, and new radiographic infiltrates especially with ground glass opacities (GGO).\n18. Patients taking antifibrotic agents at randomization who have not been on a stable dose for at least 6 weeks: these therapies could be initiated, at the discretion of their attending physicians, at or after the midpoint of their participation in STRIVE II (i.e., three months after randomization).\n19. Patients whose oxygen requirements at rest (per an arterial oxygen saturation \\[SaO2\\] \\>0.92) cannot be met with simple nasal cannula at \\\u003C10L\u002Fmin.\n20. Patients who are not expected to survive 180 days or, in the opinion of the local attending physician, have a high likelihood of not tolerating the trial interventions due to underlying comorbidities or frailties.\n21. \\>10% of whole lung images are emphysematous on High Resolution CT scan\n\n    \\-","85 Years",{"count":113,"type":20},52,[23],"This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIg) for treatment of patients with progressive idiopathic pulmonary fibrosis (IPF).",[26],[118,119],"Progression","Autoantibodies","NOT_YET_RECRUITING","2026-06-29",{"date":95,"type":37},{"date":124,"type":20},"2026-10-01",{"date":126,"type":20},"2031-03-31",{"name":128,"class":129},"University of Alabama at Birmingham","OTHER",9,{"id":132,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":24,"conditions":135,"keywords":136,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":139,"leadSponsor":140,"locationsCount":141},"100614812",{"count":19,"type":20},[23],[26],[26,28,29,30,31,32],{"date":95,"type":37},{"date":39,"type":37},{"date":41,"type":20},{"name":43,"class":44},47,{"id":143,"slug":4,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":148,"sex":149,"minAge":81,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":153,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":163,"leadSponsor":165,"locationsCount":103},"100645244","NCT07682337","Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects","A First-in-Human, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Food Effect of SCB0020160 After Oral Administration in Healthy Adult Male Subjects","Inclusion Criteria:\n\n* Healthy adult male volunteers in the opinion of the principal investigator or delegate, aged 18 to 65 years at screening\n* Body weight more Than or equals to 45.0 kilograms per square meter at screening, with a body mass index (BMI) of more than or equals to18.0-kilogram Meter square and less than or equals to 32.0 Kilograms per meter square\n\n  * Body Mass Index (BMI, kilograms per square meter.) = Weight (kilogram)\u002F\\[Height square meter\\]\n* Eligible to participate in the study based on the results of physical examination, clinical laboratory tests, history taking, and other examinations performed at screening, as determined by the principal investigator or delegate\n* Has voluntarily decided to participate and provided written or electronic consent to comply with the precautions after receiving a full explanation of the study and fully understanding it\n\nExclusion Criteria:\n\n* Has a history of or currently has any disease, including clinically significant hepatobiliary (severe liver impairment, viral hepatitis, etc.), renal (severe renal impairment, etc.), neurological, immunological, respiratory, digestive, endocrine, hematologic and oncologic, cardiovascular (Torsades de pointes, etc.), urological, psychiatric (mood disorders, obsessive compulsive disorder, etc.), and sexual function disorders\n* Has a history of or currently has a gastrointestinal disease (Crohn's disease, ulcerative colitis, etc.) that may affect the safety and pharmacokinetic evaluation of the investigational product, or has a history of gastrointestinal surgery (except for simple appendectomy or hernia surgery)\n* Has a history of hypersensitivity to the active pharmaceutical ingredient and components of the investigational product, drugs in the same class as the active pharmaceutical ingredient, or other drugs (aspirin, antibiotics, etc.)\n* Has genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose galactose malabsorption\n* Has any of the following results in vital signs measured in a sitting position after resting for at least 5 minutes at screening\n* Systolic blood pressure more than 80 millimeters of mercury or greater than or equal to140 mmHg\n* Diastolic blood pressure less than 45 millimeters of mercury or greater than or equal to140 mmHg 90 millimeters of mercury\n* Pulse rate less than 45 beats\u002Fmin or \\> 105 beats\u002Fmin\n* Has any of the following results in the 12-lead electrocardiogram measured in a semi-supine position after resting for at least 5 minutes at screening, or has clinically significant rhythm findings\n* QTcF less than 450 msec\n* Has any of the following results in the screening clinical laboratory tests\n* Estimated Glomerular Filtration Rate (eGFR) (CKD-EPI equation) \\\u003C 90 mL\u002Fmin\u002F1.73 m²\n* Fasting serum glucose more than 5.4 millimoles per liter. or less than 3.0 millimoles per liter.\n* AST or ALT 1.5 X the upper limit of normal (ULN)\n* Total cholesterol less than 5.5 millimoles per liter\n* Triglyceride less than 2.0 millimoles per liter.\n* Drinks alcohol persistently (less than 21 units\u002Fweek, 1 unit = 10 gram = 12.5 milli liter of pure alcohol) or is unable to refrain from alcohol consumption from 3 days prior to the expected first dose of the investigational product until the end of the study\n* Tested positive for the breath alcohol test at screening or at check-in on D-1 10) Smokers (However, those who quit smoking 3 months prior to the expected first dose of the investigational product may be eligible as subjects)\n* Tested positive for the urine cotinine test at screening or at check-in on D-1, even if they do not smoke\n* Has taken any prescribed drugs or herbal medicines within 2 weeks prior to the expected first dose, or has taken any over-the-counter (OTC) drugs, health functional foods including liver supplements, or vitamins within 1 week (However, they may participate in the study if the investigator deems their other conditions appropriate), or is expected to take any of the said agents\n* Has taken drugs that induce drug-metabolizing enzymes, such as barbiturates, or drugs that inhibit drug metabolism, such as clarithromycin, within 1 month prior to the expected first dose\n* Has a history of alcohol or drug abuse, or has shown a positive result for abused drugs in a urine drug test at screening or at check-in on D-1\n* Has participated in another study (including bioequivalence studies) and received an investigational product within 3 months prior to the first dose\n* Has donated whole blood within 2 months, donated blood components within 1 month, or received a blood transfusion within 1 month prior to the expected first dose\n* Has persistently consumed excessive amounts of caffeine (\\> 5 units\u002Fday, 1 unit = 80 mg of caffeine), or is unable to refrain from consuming caffeine-containing foods (coffee, tea (black tea, green tea, etc.), carbonated beverages, coffee-flavored milk, health tonics, energy drinks, etc.) from 3 days prior to the expected first dose of the investigational product until the end of the study\n* Has consumed grapefruit, grapefruit juice, or grapefruit-containing foods from 3 days prior to the expected first dose of the investigational product until the end of the study, or is unable to refrain from consuming grapefruit-containing foods during this period\n* Has unusual eating habits (e.g., consuming more than 1L of grapefruit juice per day) or is unable to consume the standard diet provided by the study site during the inpatient period\n* Tested positive for serological tests (hepatitis B test, hepatitis C test, human immunodeficiency virus (HIV) test, syphilis test)\n* Subjects who, or whose spouse (or partner) is a woman of childbearing potential, are unable or unwilling to use methods of contraception considered highly effective for the entire period of the study and for at least 90 days after the last dose of the investigational product, and who do not agree to avoid donating sperm\u002Feggs during this period.\n\n\\[Methods of contraception considered highly effective\\]\n\n* Intrauterine devices and intrauterine hormone-releasing systems with a proven contraception failure rate (\\\u003C 1%\u002Fyear) plus the use of a male condom\n* Bilateral tubal occlusion or bilateral tubal ligation plus the use of a male condom\n* Azoospermia is confirmed by sperm test after vasectomy\n* Hormonal contraception (e.g., combined oral contraceptive, progestogen-only oral contraceptive), contraceptive patch, vaginal ring, injection, subdermal contraceptive implant); however, hormonal contraception is limited to cases where it is being used for 28 days or longer prior to the administration of the investigational product and can be continuously used during the study period and up to 90 days after the last dose plus the use of a male condom.\n* Sexual abstinence, if it is the usual and preferred method of contraception.\n* Those judged by the principal investigator or delegate to be ineligible for participation in the study for reasons other than the above-mentioned criteria (non-compliance with instructions, etc.)",true,"MALE","65 Years",{"count":152,"type":20},74,[154],"PHASE1","This study aims to evaluate the safety, tolerability, pharmacokinetics, and food effect of a new investigational medicine called SCB0020160 in healthy adult men. This is the first time SCB0020160 will be administered to humans.\n\nHealthy adult men aged 18 to 65 years who meet the study eligibility criteria.\n\nStudy details\n\nParticipants will be randomly assigned to receive either SCB0020160 or placebo. The study includes single-dose and multiple-dose treatment periods, as well as an assessment of the effect of food on the absorption of SCB0020160.\n\nParticipants will undergo safety assessments including physical examinations, vital signs, ECGs, blood and urine tests, and monitoring of adverse events. The study will also assess how SCB0020160 is processed by the body.\n\nThere is no direct health benefit expected from participation. The results may help determine safe dose levels and support future clinical development of SCB0020160.",[157,158,26],"Solid Tumor","Obesity","2026-06-26",{"date":161,"type":37},"2026-07-02",{"date":121,"type":20},{"date":164,"type":20},"2027-07-01",{"name":166,"class":44},"SCBIO Inc.",{"id":168,"slug":4,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":148,"sex":16,"minAge":81,"maxAge":111,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":103},"100553634","NCT06488638","Pilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF)","BEET-IPF","IPF Patients: Inclusion Criteria\n\n1. Patients aged 18-85 years with a prior specialist multidisciplinary team diagnosis of idiopathic pulmonary fibrosis (IPF) based on current established consensus guidelines.\n2. Medical Research Council (MRC) breathlessness grade 1-3\n3. Judged clinically stable for 3 months prior to recruitment by the investigator.\n\nIPF Patients: Exclusion Criteria\n\n1. Baseline spirometry with FEV1\u002FFVC ratio \\\u003C 0.7.\n2. Neoplastic disease undergoing treatment or active follow up.\n3. Presence of infection or exacerbation requiring hospitalization, within last 3 months.\n4. Current tobacco smoker or use of nicotine containing vapes (within 3 months)\n5. Current use of ambulatory or long-term oxygen therapy (LTOT).\n6. Peripheral oxygen saturations \\\u003C85% during 6-minute walk-test.\n7. Any condition which would prevent completion of cycle-ergometer testing, pulmonary function testing (PFT) or 6-minute walk testing as judged by the investigator.\n8. Participation in a pulmonary rehabilitation (PR) program in the last 3 months.\n9. Any condition excluding CPET based on the absolute contraindication as the ACCP\u002FATS guidelines 2003\n10. Positive pregnancy test in females of childbearing age.\n11. Symptomatic peripheral vascular disease\n12. Concomitant use of nitrate-based medicine or phosphodiesterase V inhibitors\n\nControls: Inclusion Criteria\n\n1\\) Age and sex-matched to participants in the IPF cohort. Note: the participants will be age-matched within a 5-year age bracket.\n\nControls: Exclusion Criteria\n\n1. Inability to give informed written consent.\n2. Malignancy (except localised squamous or basal cell skin carcinoma) undergoing active investigation, treatment, or follow-up.\n3. Significant cardiorespiratory disease as judged by the investigator.\n4. Diabetes mellitus requiring treatment with pharmacology therapy.\n5. Current tobacco smoker or use of nicotine containing vapes (within three months).\n6. Symptomatic peripheral vascular disease.\n7. Concomitant use of nitrate-based medicine or phosphodiesterase V inhibitors.",{"count":174,"type":20},16,[176],"NA","Idiopathic pulmonary fibrosis (IPF) is a type of scarring (fibrotic) lung disease. Reduced exercise capacity is a key symptom experienced by patients. In previous research the investigators identified that an interval-based exercise programme led to significant improvements in exercise capacity (Wallis et al Antioxidants. 2023).\n\nAn unexpected finding was that in patients with IPF, exercise led to a reduction in blood nitrite concentrations an observation the investigators did not see in non-affected individuals. Research has identified that nitrite concentrations are expected to increase after exercise and the size of this increase is related to an individual's exercise capacity. There is also evidence from healthy individuals and patients with chronic obstructive pulmonary disease (COPD) that nitrate supplementation (a source of nitrite) improves response to exercise training. However, in both these groups an exercise-induced fall in blood nitrite concentrations has not been observed. Hence our finding of an exercise-induced fall in blood nitrite levels in IPF patients suggest that they may be especially sensitive to supplementation with nitrate, commercially available as nitrate-rich beetroot juice (NRBJ).\n\nThis current study investigates this in a pilot placebo-controlled, double-blind, randomised, cross-over study of NRBJ on exercise capacity in IPF patients.\n\nAims In patients with IPF\n\n* Quantify the effect of nitrate supplementation on exercise capacity\n* Determine the effect of nitrate supplementation on blood markers of nitric oxide production\u002Fmetabolism.\n* Determine the effect of nitrate supplementation on forearm blood flow. Sample size: n=8 IPF patients, aged 18-85years and medical research breathlessness scale 1-3 Intervention: 3-days (two-times daily) NRBJ or nitrate-depleted placebo juice (both commercially available) with subsequent constant-load exercise test (Primary outcome). Following at least 1 week wash-out period participants will cross-over and repeat.\n\nA cohort (n=8) of age, sex-matched controls without IPF will be enrolled for comparison of forearm blood flow and pre-exercise venous blood samples for biomarkers comparison only.\n\nNumber of sites: 1",[26,88],{"date":69,"type":37},{"date":181,"type":37},"2026-02-13",{"date":183,"type":20},"2027-06-03",{"name":185,"class":129},"University Hospital Southampton NHS Foundation Trust",{"id":187,"slug":4,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":188,"targetDuration":4,"studyType":21,"phases":189,"briefSummary":57,"conditions":190,"keywords":191,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":195,"leadSponsor":196,"locationsCount":103},"100645054",{"count":55,"type":20},[23],[26,59],[61,62,63,64,65],"2026-06-25",{"date":95,"type":37},{"date":69,"type":20},{"date":71,"type":20},{"name":73,"class":44},{"id":198,"slug":4,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":21,"phases":206,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":220},"100534422","NCT06238622","A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast","An Open-label Extension Trial of the Long-term Safety and Efficacy of BI 1015550 Taken Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) (FIBRONEER™-ON)","FIBRONEER™-ON","Inclusion Criteria:\n\n1. Patients who completed treatment in the parent trials (1305-0014, 1305-0023, or 1305-0035) without prematurely discontinuing treatment permanently according to protocol (i.e. completed treatment with or without temporary treatment interruption)\n2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial\n3. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. WOCBP taking oral contraceptives (OCs) also have to ensure the use of one barrier method during sexual intercourse with their partner, e.g., condom to account for the risk of potentially reduced efficacy of the OCs in the event of severe vomiting and diarrhoea. For France, fertile males must be ready and able to use acceptable methods of birth control\n\nExclusion Criteria:\n\n1. Any disease that may put the patient at risk when participating in this trial at investigator's discretion.\n2. Patient exhibits suicidality, in the clinical judgment of the investigator or according to the following criteria at Visit 1:\n\n   * any suicidal behaviour (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behaviour)\n   * any suicidal ideation of type 4 or 5 in the Columbia-Suicide Severity Rating Scale (C-SSRS) (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent)\n3. Patients with clinically relevant severe depression at investigator's discretion or a Hospital Anxiety and Depression Scale (HADS) subscore \\>14 at Visit 1.\n4. An occurrence of malignant neoplasm other than appropriately treated basal cell carcinoma or in situ squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix at Visit 1.\n5. Patient will undergo lung transplantation, with an assigned date of surgery.\n6. Patients with a Body Mass index (BMI) \\\u003C18.5 kg\u002Fm² that experienced an additional, unexplained and clinically significant (\\>10%) weight loss during the parent trial\n7. At Visit 1, patients with ongoing Adverse Event of Special Interest (AESI), except for latent tuberculosis (suspected vasculitis, Drug Induced Liver Injury (DILI), severe infections) that led to temporary treatment interruption in the parent trial\n8. Patients who must or wish to take restricted medications or any drug considered likely to interfere with the safe conduct of the trial.\n\nFurther exclusion criteria apply.",{"count":205,"type":20},1700,[207],"PHASE3","This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550.\n\nThe goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need to go to the hospital, or die.\n\nEvery participant takes nerandomilast as tablets for up to 1 year and 10 months. The participants may also continue their regular treatment for pulmonary fibrosis during the study.\n\nParticipants visit their doctors regularly. During these visits, the doctors collect information on any health problems of the participants. Participants also regularly do lung function tests.",[26,210],"Progressive Pulmonary Fibrosis","2026-06-23",{"date":213,"type":37},"2026-06-24",{"date":215,"type":37},"2024-05-06",{"date":217,"type":20},"2027-05-05",{"name":219,"class":44},"Boehringer Ingelheim",372,{"id":222,"slug":4,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":21,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":4},"100644504","NCT07671911","Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Chronic Cough in Participants With Idiopathic Pulmonary Fibrosis","OCEAN-1","Inclusion Criteria:\n\n* Diagnosis of IPF as determined by the Investigator based on American Thoracic Society (ATS)\u002FEuropean Respiratory Society (ERS)\u002FJapanese Respiratory Society (JRS)\u002FLatin American Thoracic Society (ALAT) clinical practice guidelines.\n* Chronic cough for ≥8 weeks prior to Screening.\n* PGI-Severity Score ≥ 2 at Screening.\n* Forced vital capacity (FVC) ≥40 percent (%) of predicted at Screening.\n* Diffusing capacity for carbon monoxide (DLCO) ≥25% of predicted during Screening or within 12 weeks prior to Screening.\n* Participants who are currently taking antifibrotic medication (e.g., nintedanib, pirfenidone, nerandomilast) should be on a stable dose for at least 6 weeks prior to the Baseline Visit.\n\nExclusion Criteria:\n\n* Clinical diagnosis or clinical suspicion of an upper or lower respiratory tract infection in the last 8 weeks prior to the Screening visit or during Screening.\n* Hospitalization for any respiratory illness (including acute exacerbation of IPF) within 2 months prior to Screening.\n* Diagnosed sleep apnea or currently on any treatment for sleep apnea \\[example (e.g.), Continuous Positive Airway Pressure (CPAP)\\].\n\nNote: Other protocol-defined inclusion\u002Fexclusion criteria may apply.",{"count":229,"type":20},306,[207],"The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).",[26],"2026-06-22",{"date":159,"type":37},{"date":236,"type":20},"2026-06",{"date":238,"type":20},"2028-07",{"name":240,"class":44},"Trevi Therapeutics",{"id":242,"slug":4,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":21,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":258},"100595751","NCT07036523","A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment","A Double-blind, Randomised, Placebo-controlled, Parallel Group, Phase IIa Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BI 765423 Administered Intravenously With or Without Standard of Care in Patients With Idiopathic Pulmonary Fibrosis","Inclusion Criteria :\n\n1. 40 years of age or older at the time of informed consent signature.\n2. Signed and dated written informed consent in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.\n3. Male or female patients. Male patients with Woman of childbearing potential (WOCBP) sexual partners must use contraception (male condom) to avoid exposure via seminal fluid during treatment and for a specific period after last drug intake. Women can only be included if they are of non-childbearing potential, defined as meeting at least one of the below conditions:\n\n   * Permanently surgically sterilised (hysterectomy, bilateral salpingectomy and\u002For bilateral oophorectomy)\n   * Postmenopausal, defined as no menses for 12 months without an alternative medical cause. In questionable cases of postmenopausal status:\n\n     * Women not using sex hormone medication such as hormone replacement therapy may be included if a blood sample confirms levels of follicle stimulating hormone (FSH) \\> 40 U\u002FL and estradiol \\\u003C 30 ng\u002FL\"\n4. Patients with a documented diagnosis of IPF prior to Visit 1, confirmed by the investigator as per the 2022 American Thoracic Society (ATS)\u002FEuropean Respiratory Society (ERS)\u002FJapanese Respiratory Society (JRS)\u002FLatin American Thoracic Association (ALAT) Guideline and, if available, surgical lung biopsy or transbronchial lung cryobiopsy histopathology report.\n5. Patients with a high-resolution computed tomography (HRCT) taken within 12 months of Visit 1 (or during the screening period, if not available) confirming \"UIP\" or \"probable UIP\" HRCT pattern consistent with the clinical diagnosis of IPF by central review (prior to Visit 2).\n\n   * Patients with an \"indeterminate\" HRCT finding are eligible if a clinical diagnosis of IPF can be confirmed based on an historical histopathology report of a surgical lung biopsy or cryobiopsy demonstrating a \"UIP\" or \"Probable UIP\" pattern.\n   * Patients with an \"alternative diagnosis\" HRCT finding are eligible if a clinical diagnosis of IPF can be confirmed based on an historical histopathology report of a surgical lung biopsy or cryobiopsy demonstrating a \"UIP\" pattern.\"\n6. Patients with an extent of fibrosis ≥20% as per an HRCT of the chest performed within 12 months prior to Visit 1 or during the screening period (if not available) and confirmed by central review.\n7. Patients with a Forced vital capacity (FVC) ≥45% predicted at Visit 1. Predicted normal values will be calculated according to Global Lung Initiative (GLI).\n8. Patients with haemoglobin-corrected diffusing capacity of the lungs for carbon monoxide (DLCO) ≥20% predicted at Visit 1.\n\nFurther inclusion criteria apply.\n\nExclusion criteria:\n\n1. Acute exacerbation of IPF within at least 12 weeks prior to Visit 1 and\u002For during the screening period (investigator-determined).\n2. Relevant airways obstruction (pre-bronchodilator forced expiratory volume in 1 second (FEV1)\u002FFVC \\\u003C0.7) at Visit 1.\n3. Lower respiratory tract infection requiring treatment within 4 weeks prior to Visit 1 and\u002For during the screening period.\n4. Significant PH defined by any of the following:\n\n   * Previous clinical or echocardiographic evidence of significant right heart failure according to investigator's judgement\n   * History of right heart catheterisation showing a cardiac index ≤2 L\u002Fmin\u002Fm\\^²\n   * PH requiring parenteral therapy with prostanoids\n5. On nintedanib or pirfenidone treatment for less than 12 weeks prior Visit 1, planning to start nintedanib or pirfenidone within the first 12 weeks of investigational medicinal product (IMP) treatment or on combined nintedanib plus pirfenidone treatment. Newly diagnosed patients considered in need of SoC treatment by the treating physician, who would be withheld SoC treatment only for the sake of participation in the trial, should also be excluded.\n6. Cardiovascular comorbidities including\n\n   * Severe hypertension (uncontrolled under treatment≥160\u002F100 mmHg at multiple occasions) within 3 months of Visit 1\n   * Myocardial infarction, stroke, or transient ischemic attack within 6 months of Visit 1\n   * Unstable cardiac angina within 6 months of Visit 1\n7. Life expectancy for any concomitant disease other than IPF \\\u003C2.5 years (investigator assessment).\n\nFurther exclusion criteria apply.",{"count":248,"type":20},71,[23],"This study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or equal to 45% of the predicted value and fibrosis of 20% or more confirmed by a high-resolution computed tomography (HRCT) scan. The purpose of this study is to find out if a medicine called BI 765423 can improve lung function in people with IPF. The study will compare BI 765423 with a placebo to see if there is a difference in lung capacity after 3 months of treatment and will also look at changes in certain markers related to lung health.\n\nParticipants are put into two groups randomly, which means by chance. One group receives the study medicine, and the other group receives a placebo. Placebo looks like BI 765423 but does not contain any study medicine. The study medicine is given as an infusion into a vein every four weeks.\n\nParticipants are in the study for 8-10 months. During the study, participants may continue their regular treatment for IPF. During the study they visit the study site several times for screening, treatment, and follow-up. Doctors regularly test lung function by measuring FVC and take blood samples to measure study endpoints. The results are compared between the two groups to see whether the treatment works. The doctors also check participants' health and take note of any unwanted effects.",[26],{"date":213,"type":37},{"date":254,"type":37},"2025-11-13",{"date":256,"type":20},"2027-06-22",{"name":219,"class":44},46,{"id":260,"slug":4,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":21,"phases":267,"briefSummary":268,"conditions":269,"keywords":270,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":283,"leadSponsor":285,"locationsCount":287},"100590468","NCT06967805","WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)","A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)","Inclusion Criteria:\n\n* Participants with IPF of any gender ≥ 40 years of age at time of signing the informed consent.\n* Able to understand the study and provide signed, written informed consent.\n* Able to read and understand the language of the informed consent and other study-related materials.\n* Meet the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association (ATS\u002FERS\u002FJRS\u002FALAT) 2019 criteria for the diagnosis of IPF; Diagnosed with IPF within 7 years of screening.\n* If a participant is on treatment with pirfenidone, nintedanib, or nerandomilast, the dose of the medication must be stable for ≥ 90 days prior to Screening with plans to maintain the same dose throughout the study. Use of any of these 3 agents in combination with each other is not permitted.\n* If a participant was on treatment with pirfenidone, nintedanib, or nerandomilast, and the agent has been discontinued, this must have occurred ≥ 30 days prior to Screening. At Screening, there must also be no plan to start either of these medications for the duration of the study. Participants newly diagnosed with IPF who, in the judgment of the treating physician, are considered in need of treatment with nintedanib, pirfenidone, or nerandomilast should not defer standard of care treatment and should be excluded from the study.\n* FVC of ≥ 45 percent predicted (pp) at screening.\n* DLCO of ≥ 25pp at screening.\n* Willing and able to complete all protocol required study visits and procedures.\n* Female participants of childbearing potential must have a negative serum pregnancy test at Screening.\n* Participants with reproductive potential must agree to use and follow medically approved highly effective methods of contraception during treatment and until 5 half-lives or 125 days after the last dose of study drug, whichever is longer.\n* Male participants with female partners of childbearing potential must use condoms during the treatment and until 5 half-lives or 125 days after the last dose of study drug, whichever is longer.\n\nExclusion Criteria:\n\n* Acute exacerbation of IPF within 6 months of Screening or during the Screening Period.\n* Forced expiratory volume in 1 second (FEV1)\u002FFVC ratio of \\\u003C0.7 at Screening.\n* Requirement for continuous supplemental oxygen. Intermittent supplemental oxygen use (e.g., during exercise or sleep) is permitted.\n* Expected to receive a lung transplant within the study duration.\n* Current active bacterial infection or use of antibiotics for suspected lung infection in the 30 days prior to Screening.\n* Planned surgery within the study duration.\n* Clinically significant pulmonary hypertension.\n* Use of immunosuppressive therapy (excluding corticosteroids). If previously on such agents, they should have been discontinued for at least 5 half-lives or 90 days, whichever is longer, prior to Screening.\n* Use of systemic corticosteroids (prednisone or equivalent) at a dose \\> 10 mg once daily within 30 days of Screening.\n* Currently smoking or vaping.\n* Current known malignancy, or history of cancer, or lymphoproliferative disorder other than non-melanomatous skin cancers, within 2 years of Screening.\n* Current infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).\n* Currently pregnant, breast feeding, or planning to conceive for the length of the study.\n* History of severe depression, psychosis, or suicidal ideation, as determined by the Investigator, within 2 years of Screening.\n* Any clinically significant disease or laboratory abnormality detected at Screening that might interfere with a participant's ability to complete the study, on-study evaluations, or participant safety.\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 2× upper limit of normal (ULN) at Screening.\n* Presence of interstitial lung disease due to any cause other than IPF, clinically significant cardiovascular disease, or any other concurrent active medical condition determined by the Investigator to interfere with the participant's ability to complete the trial.\n* Known allergy to MTX-463 or any of its excipients, or a history of a prior allergic reaction to a monoclonal antibody therapeutic.\n* Any prior use of MTX-463 or other therapy targeting WISP1.\n* Any other concurrent experimental agent or an active part of any other clinical study, unless they have stopped taking the investigational product at least 5 half-lives or 30 days before Screening, whichever is longer.",{"count":266,"type":20},164,[23],"A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)",[26],[271,272,30,26,273,274,275,276,277,278],"MTX-463-I201","MTX-463","Adult","Fibrosis","Monoclonal Antibody","MAB","FVC","WISPer","2026-06-10",{"date":281,"type":37},"2026-06-12",{"date":97,"type":37},{"date":284,"type":20},"2027-08",{"name":286,"class":44},"Mediar Therapeutics",69,{"id":289,"slug":4,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":148,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":295,"phases":4,"briefSummary":296,"conditions":297,"keywords":301,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":103},"100092968","NCT00470327","A Study of the Natural Progression of Interstitial Lung Disease (ILD)","Inclusion Criteria:\n\n* Interstitial lung disease\n\nExclusion Criteria:\n\n* Does not have Interstitial lung disease",{"count":294,"type":20},4000,"OBSERVATIONAL","We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the \"phenotypic\" expression of these diseases.",[298,26,299,300],"Interstitial Lung Diseases","Sarcoidosis","Connective Tissue Disorder",[302,303,299,304],"Interstitial lung diseases","idiopathic pulmonary fibrosis","mRNA and cytokine expression","2026-06-05",{"date":307,"type":37},"2026-06-09",{"date":309,"type":37},"2005-09",{"date":311,"type":20},"2030-12",{"name":313,"class":129},"University of Chicago",{"id":315,"slug":4,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":319,"targetDuration":4,"studyType":21,"phases":321,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":103},"100390340","NCT04362644","Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis","Inclusion Criteria:\n\n1. Age between 40-85 years old.\n2. A diagnosis of IPF that fulfills American Thoracic Society (ATS) \u002F European Respiratory Society (ERS) 2018 consensus criteria within 5 years.\n3. Ability and willingness to give informed consent and adhere to study requirements.\n4. Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1\u002FFVC) \\>0.70.\n5. High or mixed affinity binder for TSPO ligands based on genotyping for single-nucleotide polymorphism (SNP)rs6971.\n\nExclusion Criteria:\n\n1. Acute exacerbation of IPF within \\\u003C30 days\n2. Diagnosis of Diabetes Mellitus (Type 1 or Type 2).\n3. Diagnoses of current infection by clinical or microbial assessments.\n4. Treatment for \\>14 days within the preceding month with \\>20 mg. prednisone (or equivalent) or any treatment during the last month with a cellular immunosuppressant.\n5. Subjects with prior radiation therapy to the thorax.\n6. Women who are pregnant, or who are breastfeeding. IPF is a disease of older adults, and male predominant, so this will not be a frequent consideration.\n7. Severe cardiovascular disease, defined as any of the following within the preceding 12 weeks: acute myocardial infarction or unstable angina, a coronary revascularization procedure, or stroke.\n8. Subjects with known liver disease.\n9. Diagnosis of any active cancer with the exception of basal cell carcinoma of skin.\n10. Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.\n11. Active cigarette smoking or vaping",{"count":320,"type":20},10,[154],"The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose (\\[18F\\] FDG) and fluorine-18 Displacement Per Atom (\\[18F\\]DPA-714) using positron emission tomography and computed tomography (PET\u002FCT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.",[26],"2026-05-30",{"date":326,"type":37},"2026-06-02",{"date":328,"type":37},"2020-12-08",{"date":330,"type":20},"2027-06",{"name":128,"class":129},{"id":333,"slug":4,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":21,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":347,"leadSponsor":349,"locationsCount":4},"100637831","NCT07600021","A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis.","Inclusion Criteria:\n\n* 1\\. Age ≥ 40 years, regardless of gender;\n* 2\\. The investigator confirms the clinical diagnosis of IPF in participants based on chest HRCT, surgical lung biopsy, or transbronchial lung cryobiopsy (if available) performed during the screening period or within 1 year prior to screening (see Appendix 13.7 for details);\n* 3\\. FVCpp ≥ 45% during the screening period;\n* 4\\. Hemoglobin-corrected DLCOpp ≥ 25% and \\\u003C 90% during the screening period;\n* 5\\. Received a single stable-dose antifibrotic therapy for at least 12 weeks prior to screening (concurrent use of nintedanib and pirfenidone is prohibited) and will continue after randomization; or had not received stable antifibrotic therapy, or had discontinued such therapy for at least 8 weeks, with no plan to initiate antifibrotic therapy during the trial;\n* 6\\. Understands the purpose and risks of this study, comprehends and agrees to comply with all study procedures, consents to participate, and provides written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Interstitial lung disease other than IPF.\n* 2\\. Airway obstruction during screening (FEV₁\u002FFVC \\\u003C 0.7), or emphysema greater than pulmonary fibrosis on HRCT.\n* 3\\. Confirmed or suspected acute exacerbation of IPF within 3 months prior to screening.\n* 4\\. Investigator judgment that IPF severity showed sustained improvement during the 12 months prior to screening, based on changes in FVC, DLCO and\u002For HRCT findings.\n* 5\\. Other clinically significant respiratory diseases during screening.\n* 6\\. Severe diseases in any other system (cardiovascular, digestive, neurological, hematological, endocrine) during screening.\n* 7\\. Malignancy within 5 years prior to screening (excluding treated basal cell carcinoma of the skin, in situ squamous cell carcinoma of the skin, or carcinoma in situ of the cervix).\n* 8\\. Any acute infection within 2 weeks prior to screening that has not fully recovered per investigator judgment.\n* 9\\. Active, unstable or uncontrolled vasculitis within 8 weeks prior to screening.\n* 10\\. Any acute or chronic active infection during screening.\n* 11\\. C-SSRS assessment during screening indicating suicidal behavior within the past 2 years (actual attempt, interrupted attempt, aborted attempt, or preparatory acts or gestures), or clinically significant suicidal ideation within 3 months prior to screening or during screening (participant answered \"yes\" to C-SSRS suicidal ideation question 4 or 5).\n* 12\\. Treatment with PDE1, PDE3, PDE4, PDE10 inhibitors, or non-selective PDE inhibitors within 4 weeks prior to screening.\n* 13\\. Use of strong CYP3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is longer) before the first dose of investigational product, or inability to discontinue such agents during the study.\n* 14\\. Receiving immunomodulatory agents (excluding oral glucocorticoids) for respiratory or pulmonary conditions during screening, or prednisone (or equivalent) at a daily dose \\> 15 mg.\n* 15\\. Abnormal hepatic and renal function during screening: ALT, AST \\> 2.5 × ULN, or TBIL \\> 1.5 × ULN, or eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m².\n* 16\\. Severe, persistent, uncontrolled hypertension during screening (SBP ≥ 180 mmHg or DBP ≥ 100 mmHg).\n* 17\\. History of smoking within 3 months prior to screening or unwillingness to abstain from smoking (including e-cigarettes) during the study.\n* 18\\. Hypersensitivity to SYH2059 or any excipients, or history of severe drug allergy.\n* 19\\. Participation in any clinical trial within 4 weeks prior to screening (excluding those not receiving investigational product).\n* 20\\. Participation in a clinical study of the same target drug and receipt of treatment within 3 months prior to screening.\n* 21\\. Pregnant or lactating females; fertile females or males unwilling to practice strict contraception throughout the trial and for 3 months after trial completion until the end of the safety follow-up period (including male participants).\n\nAny other conditions deemed inappropriate for trial participation by the investigator.\n\n* 22\\. Additional Exclusion Criteria (for PK intensive sampling participants):\n* 23\\. Previous history of gastrointestinal surgery that may interfere with the PK of the investigational product.\n* 24\\. Alcohol consumption exceeding 14 units per week within 4 weeks prior to screening.\n* 25\\. Habitual excessive intake of xanthine- or caffeine-containing foods, beverages, or other substances affecting drug absorption, distribution, metabolism or excretion within 4 weeks prior to screening.",{"count":339,"type":20},156,[23],"This is a multicenter, randomized, double-blind, placebo-controlled Phase II study. It Aims aims to evaluate the efficacy and safety of different doses of SYH2059 tablets compared with placebo in adult patients with IPF, observe the PK profile of SYH2059 tablets in adult IPF patients, and assess the population pharmacokinetic (PPK) profile, exposure-response (E-R) relationship, as well as the changing trends of blood biomarkers.",[26],"2026-05-14",{"date":345,"type":37},"2026-05-20",{"date":69,"type":20},{"date":348,"type":20},"2027-12-30",{"name":350,"class":44},"InnovStone Therapeutics Limited",{"id":352,"slug":4,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":148,"sex":16,"minAge":357,"maxAge":150,"enrollmentInfo":358,"targetDuration":4,"studyType":21,"phases":360,"briefSummary":361,"conditions":362,"keywords":363,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":74},"100627873","NCT07454291","A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants","A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 in Healthy Participants","Inclusion Criteria:\n\n* Participants are reproductively sterile.\n* Body Mass Index (BMI) ≥ 18.5 and ≤ 32 kg\u002Fm2 and body weight ≥ 50 kg at study start.\n* Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, or electrocardiograms (ECGs) prior to dosing, as deemed by the Investigator.\n* Able to swallow multiple capsules and tablets.\n* Participants are willing to remain on study treatment for the duration of the study and comply with all study days and procedures.\n* Participants willing to sign and have a full understanding of the informed consent.\n* Participants must be willing to be sequestered for the time period indicated for their respective cohort.\n\nExclusion Criteria:\n\n* Chronic or current use of any prescription or over the counter medications; or acute use of prescription medications within 14 days or 5 half-lives, whichever is longer, or over the counter medications within 7 days or 5 half-lives, whichever is longer, prior to study start, or planned use during all study periods.\n* Participant is unwilling to refrain from fruits (including juices) that inhibit CYP3A4, including grapefruit, Seville orange, pomelo, or star fruit, beginning 7 days prior to study start through end of study.\n* Active infection with hepatitis B or C, or human immunodeficiency virus (HIV) during screening.\n* Current alcohol or drug abuse.\n* Smoking or other nicotine use (including but not limited to vaping, nicotine patch, nicotine gum or nicotine lozenge) within 3 months prior to screening, current smoker, or unwillingness to refrain from smoking for the duration of the study.\n* History or presence (per participant history) of:\n\n  1. Autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus\n  2. Thrombophlebitis or deep vein thrombosis\n  3. Hematologic or coagulation disorders\n  4. Liver disease or dysfunction; Gilbert's syndrome\n  5. Renal dysfunction or glomerulonephritis\n  6. Coronary artery disease\n  7. Diverticular disease\n  8. Congestive heart failure or ventricular dysfunction\n  9. Clinically significant cardiovascular, gastrointestinal, pulmonary, endocrine, central nervous system disorders, or other major active and uncontrolled disease in the opinion of the Investigator.\n* History of malignancy of any type, other than in situ cervical cancer or surgically excised non-melanomatous skin cancers, within 5 years before study start.\n* Participation in a clinical research trial that included the receipt of an investigational agent or any experimental procedure within 30 days or 5 half-lives, whichever is longer, prior to screening, during screening, or planned participation in any such trial while participating in this study.\n* Major surgery requiring hospitalization (according to the Investigator) performed within 3 months prior to screening, or planned during the course of the trial.\n* Participants with clinically significant cardiac abnormalities including but not limited to: has pacemaker; or is not in sinus rhythm during screening; or has a left bundle branch block or bifascicular block during screening; or any prior history of ventricular arrhythmia or torsades de pointes.\n* Participant is unwilling to adhere to the on-study diet provided by the clinical site during study participation.\n* Females who are pregnant or nursing.\n* Participants that are unwilling to refrain from blood or blood product donation for the duration of the study and for 30 days after their final dose of any study treatment.\n* Males who are unwilling to refrain from sperm donation for the duration of the study and for 95 days after their final dose of any study treatment.\n* Females who are unwilling to refrain from egg donation for the duration of the study and for 95 days after their final dose of any study treatment.\n* Participants with a history of a severe allergic reaction or anaphylactic reaction or known hypersensitivity to any component of taladegib (all cohorts), nintedanib (Cohort 1), or pirfenidone (Cohorts 2 and 3).\n* Participants who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study investigative site or the study Sponsor.","26 Years",{"count":359,"type":20},57,[154],"The purposes of this study are to:\n\n1. evaluate potential interactions between taladegib (ENV-101) and current standard-of-care (SOC) therapies for idiopathic pulmonary fibrosis (IPF), including nintedanib and pirfenidone, and\n2. more fully characterize the pharmacokinetics (PK) of taladegib (i.e., how the body absorbs, distributes, metabolizes and excretes taladegib).\n\nThis study will enroll 4 cohorts (groups) of participants. Each cohort will experience a different duration of treatment and sequestering (being housed) at the clinical site, followed by a 14-day follow-up period for safety evaluation. The longest duration of treatment for any cohort is 30 days.",[26],[364,365,366,367],"ENV-101","taladegib","drug-drug interaction","pharmacokinetics","2026-05-13",{"date":370,"type":37},"2026-05-15",{"date":372,"type":37},"2026-04-28",{"date":374,"type":20},"2026-10",{"name":376,"class":44},"Endeavor Biomedicines, Inc.",{"id":378,"slug":4,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":148,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":383,"targetDuration":4,"studyType":21,"phases":385,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":391,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":103},"100347151","NCT03800017","Skeletal Muscle Function in Interstitial Lung Disease","Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interstitial Lung Disease","Inclusion Criteria for ILD Patients:\n\n* Age 40-80 years (inclusive)\n* A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses\n* Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis\n* Appropriate candidate for pulmonary rehabilitation\n* 6 minute walk distance 50m or more\n* Oxygen saturation ≥ 92% by pulse oximetry at rest while breathing room air\n* Clinically stable for the preceding 6 weeks\n* Can fluently read and write in English\n\nInclusion Criteria for Healthy Controls:\n\n* Age 40-80 (inclusive)\n* Normal pulmonary function (80-120% predicted)\n* No lung or cardiovascular disease\n* Can fluently read and write in English\n\nExclusion Criteria for the ILD patients:\n\n* Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease)\n* Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and\u002For oxygenation\n* Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25%\n* Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program\n* Use of prednisone greater than 10 mg\u002Fday for more than 2 weeks within 3 months of the first study visit\n* Significant emphysema (less than 10% volume on HRCT or FEV1\u002FFVC less than 0.70)\n\nExclusion Criteria for Healthy Controls:\n\n* Currently smoking or previously smoked more than 10 pack-years\n* Any medical conditions that prevents them for exercising safely\n* Cardiac pacemaker or any metal or electronic inside the body",{"count":384,"type":20},40,[176],"Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i) examine differences in the structure and function of the leg muscles in ILD patients, ii) determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients with ILD, and iii) determine the effects of breathing extra oxygen on leg muscle fatigue, as well as ability to exercise in ILD patients.",[88,26,388,389,390],"Hypersensitivity Pneumonitis","Scleroderma","Nonspecific Interstitial Pneumonia",{"date":370,"type":37},{"date":393,"type":37},"2024-08-07",{"date":395,"type":20},"2026-12-31",{"name":397,"class":129},"University of British Columbia",{"id":399,"slug":4,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":53,"enrollmentInfo":404,"targetDuration":4,"studyType":21,"phases":406,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":74},"100504008","NCT05842681","Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis","Role of Add-on Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis","Inclusion Criteria:\n\n* Baseline disease severity classified as mild or early-moderate according to the SCALE-IPF (locked April 2023) threshold ≤ 13 points.\n* Participation within the Assiut University IPF Research Program (2022-2026).\n* Additional longitudinal therapeutic platform arms involving pirfenidone with or without azithromycin may include clinically stable idiopathic pulmonary fibrosis patients according to protocol-amended eligibility criteria approved in September 2025.\n\nExclusion Criteria:\n\n* Age: less than 18 years.\n* Patients with any severity other than mild or early-moderate acute exacerbation of IPF according to SCALE-IPF (locked April 2023).\n* Patients with multislice computed tomography with a radiological pattern rather than usual interstitial pneumonitis (UIP).\n* Unstable patients need mechanical ventilation or Respiratory Intensive Care Unit admission.\n* Patients with end-organ failure.\n* Patients with known hypersensitivity or contraindication to pirfenidone or azithromycin, significant hepatic impairment, severe drug intolerance, or other contraindications to study medications according to standard clinical judgment.",{"count":405,"type":20},1000,[176],"This randomized controlled trial evaluates the therapeutic role of azithromycin in acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF). Baseline severity classification and stratification were performed using the SCALE-IPF framework (Severity Classification and Lung Evaluation for Prognosis in IPF; locked April 2023) to ensure balanced disease severity across randomized arms. End-of-study analyses included descriptive and stratified phenotyping using the Idiopathic Pulmonary Fibrosis Phenotypes Identification Model (IPIM); locked April 2023).\n\nFollowing a protocol amendment approved in September 2025, the study expanded into a multi-arm therapeutic platform evaluating both azithromycin timing strategies and combination antifibrotic-immunomodulatory therapy in idiopathic pulmonary fibrosis. Additional treatment arms involving pirfenidone with or without azithromycin were incorporated without altering the original randomized comparisons or baseline study framework.\n\nBoth frameworks were developed within the Assiut University IPF Research Program (2022-2026), a coordinated institutional effort investigating clinical, prognostic, and therapeutic dimensions of IPF. Neither framework altered randomization procedures, treatment allocation, or study endpoints; they were applied to improve standardization, reproducibility, and interpretability of results.",[26],"2026-05-11",{"date":368,"type":37},{"date":412,"type":37},"2023-06-01",{"date":414,"type":20},"2027-02-28",{"name":416,"class":129},"Assiut University",{"id":418,"slug":4,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":21,"phases":426,"briefSummary":427,"conditions":428,"keywords":430,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":440,"locationsCount":442},"100570967","NCT06714123","Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease","Senicapoc in Patients With Progressive Fibrotic ILD (Interstitial Lung Disease) and IPF (Idiopathic Pulmonary Fibrosis) to Prevent Progression.","FIBROPOC","Inclusion Criteria:\n\n* Progressive fibrotic ILD or Progressive IPF diagnosed according to ATS\u002FERS\u002FJRS\u002FALAT guidelines at the time of diagnosis\n* Age \\> 18 years\n* HRCT historically performed within 24 months\n* FVC \\> 45 %, FEV1\u002FFVC \\> 0,7 or above LLN\n* Annual FVC decline of at least 5% predicted, based on at least three FVC measurements within 6-24 months before enrolment\n* Subject able to give informed consent.\n* The extent of fibrotic changes is greater than the extent of emphysema on the most recent HRCT scan\n* Male subjects of reproductive potential agree to use highly effective contraception\u002Fpreventive exposure measures from the time of first dose of IMP during the study, and until 90 days (male) after the last dose of IMP.\n* Female subjects agree to use highly effective contraceptive during the study, and must show a negative pregnancy test before inclution.\n* Able to walk at least 150 meters during the 6MWT at screening Visit 1;\n* Able to read and complete the EQ-5D, SGRQ-I, K-BILD questionnaire.\n\nExclusion Criteria:\n\n* Sickle cell disease\n* Any clinical condition or other condition or circumstance that, in the opinion of the investigator, may make a subject unsuitable for inclusion or unlikely or unable to complete the study or comply with study procedures and requirements.\n* Known hypersensitivity to any of the IMP ingredients or a history of a significant allergic reaction to any drug as determined by the investigator\n* A current immunosuppressive condition\n* Clinically significant abnormalities detected on ECG of either rhythm or conduction,\n* Moderate to severe hepatic impairment (Child-Pugh B or C); and\u002For abnormal LFT at screening,\n* Clinical laboratory test suggestive of cholestasis with total serum bile acid levels \\> 3xULN.\n* Abnormal renal function, defined as eGFT \\> 30 ml\u002Fkg\n* History of malignancy within the past 5 years\n* Previous participation in a clinical study with IMP for fibrotic disease within the last 6 months.\n* Concurrent participation in another interventional drug, device, or biological investigational research study, or use of an investigational agent within 5 half-lives of the agent\n* Lower respiratory tract infection requiring treatment within 4 weeks prior to screening and\u002For during the screening period.\n* History of lung volume reduction surgery or lung transplant.\n* Diagnosis of severe pulmonary hypertension\n* Unstable cardiovascular, pulmonary (other than IPF), or other disease within 6 months prior to screening or during the screening period\n* Use of any of the following therapies within 4 weeks prior to screening and during the screening period, or planned during the study: warfarin, imatinib, ambrisentan, azathioprine, cyclophosphamide, cyclosporine A, bosentan, methotrexate, sildenafil (except for occasional use), prednisone at steady dose \\> 10 mg\u002Fday or equivalent.\n* Current alcohol or substance abuse in the opinion of the investigator.",{"count":425,"type":20},140,[23],"This study will investigate whether the senicapoc drug can prevent the scarring from worsening in interstitial lung disease.\n\nResearchers will compare Senicapoc to a placebo (a look-alike substance that contains no drug) to see if Senicapoc works to prevent lung function worsening.\n\nParticipants will be asked to take 3 tablets a day for 26 weeks. Within this period, doctors will follow the participants, ask for experience of adverse events, check lung function and organ status, and participants will need to fill out quality-of-life questionnaires. A total of 5 visits are required, at initiation, after4, 13, 26 and 52 weeks. The final visit will occur 52 weeks after initiation and consist of a normal visit in the outpatient clinic where the doctor asks for relevant information regarding the period after end of administration of the study drug.",[429,26],"Pulmonary Fibrosis, Interstitial Lung Disease",[431,432,433],"pulmonary fibrosis","Senicapoc","interstitial lung disease","2026-05-06",{"date":436,"type":37},"2026-05-07",{"date":438,"type":37},"2025-08-01",{"date":71,"type":20},{"name":441,"class":129},"Vejle Hospital",5,{"id":444,"slug":4,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":21,"phases":451,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":461},"100534648","NCT06241560","A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood","An Open-label, Single-group Trial to Evaluate the Effect of Pirfenidone on the Pharmacokinetics of a Single Oral Dose of BI 1015550","Inclusion criteria:\n\n* Male or female patients aged ≥40 years old at the time of signed consent\n* Patients with idiopathic pulmonary fibrosis (IPF) and an indication\u002Fno contraindication for treatment with pirfenidone based on investigator's judgement.\n* Body mass index (BMI) of 18.5 to 29.9 kg\u002Fm\\^2 (inclusive)\n* Signed and dated written informed consent in accordance with International Conference of Harmonization-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial\n* Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control. WOCBP taking oral contraceptives (OC) also have to use one barrier method\n\nExclusion criteria:\n\n* Patients with a significant disease or condition other than IPF, which in the opinion of the investigator, may put the patient at risk because of participation, interfere with study procedures, or cause concern regarding the patient's ability to participate in the study\n* Acute IPF exacerbation within 1 month prior to Visit 1 and\u002For during the screening period (investigator-determined).\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>2.5 x ULN or total Bilirubin \\>1.5 x upper limit of normal (ULN) at Visit 1\n* Patients with underlying liver cirrhosis (Child Pugh C hepatic impairment)\n* Cardiovascular diseases, any of the following:\n\n  * Severe hypertension (uncontrolled under treatment ≥160\u002F100 mmHg at multiple occasions) within 3 months of Visit 1\n  * Myocardial infarction, stroke or transient ischemic attack within 6 months of Visit 1\n  * Unstable cardiac angina within 6 months of Visit 1\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) less than 90 ml\u002Fmin\u002F1.73 m\\^2 at Visit 1\u002Fscreening (Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] formula or Japanese version of CKD-EPI for Japanese patients)\n* Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)\n* Relevant chronic or acute infections including but not limited to human immunodeficiency virus (HIV) and viral hepatitis\n* Further exclusion criteria apply",{"count":450,"type":20},20,[23],"This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are 40 years and older. The purpose of this study is to find out whether a medicine called pirfenidone changes the amount of a medicine called BI 1015550 in the blood. Some people may take more than one medicine at a time. Therefore, it is important to understand how different medicines influence one another.\n\nParticipants take one dose of BI 1015550 as a tablet. Participants then take one tablet of pirfenidone 3 times a day for one week. The dose is then increased to 2 tablets 3 times a day for the second week. In the third week the dose is increased further to 3 tablets 3 times a day. Participants then take another dose of BI 1015550 as a tablet.\n\nParticipants are in the study for a little over 1 month. During this time, they visit the study site 15 times. Two of the visits include overnight stays at the study site. The study staff also contacts the participants by phone. During the visits, the doctors collect information about participants' health and take blood samples from the participants. They compare the amount of pirfenidone and BI 1015550 in the blood. Doctors also regularly check participants' health and take note of any unwanted effects.",[26],{"date":455,"type":37},"2026-04-29",{"date":457,"type":37},"2026-03-05",{"date":459,"type":20},"2026-08-06",{"name":219,"class":44},3,{"id":463,"slug":4,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":21,"phases":471,"briefSummary":472,"conditions":473,"keywords":474,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":103},"100632932","NCT07520110","Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis","Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis (MAVRIC)","MAVRIC","Inclusion Criteria:\n\n1. IPF diagnosis by enrolling investigator (following the 2022 updated guidelines on diagnosis and management of IPF)\n2. Age 40 years or older\n3. HbA1c \\\u003C 9% at screening\n4. High risk by proteomic signature (proteomic signature present) for participants randomized only (for participants randomized only; participants that are proteomic signature absent will undergo remote study assessments at 12 and 24 months only).\n5. If on FDA-approved treatment(s) for IPF, on a stable dose for at least 8 weeks prior to randomization\n6. Ability to provide informed consent\n\nExclusion Criteria:\n\n1. Taking metformin within 3 months of randomization\n2. Allergy or intolerance to metformin\n3. Use of insulin or insulin secretagogue(s) at randomization\n4. Pregnancy, planning to become pregnant, or lactating\n5. Women of childbearing potential not willing to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of \\\u003C1% per year during study participation\n6. History of biochemically-confirmed acidosis (lactate \\> 5.0 mmol\u002FL)\n7. Estimated glomerular filtration rate less than 45 mL\u002Fmin\u002F1.73 m2 at screening\n8. Moderate-to-severe liver disease, decompensated heart failure, or any other condition that may make the participant unsuitable for inclusion as assessed by the study investigator at each site\n9. Receipt of an investigational study agent as part of a therapeutic trial within 30 days of the Screening Visit (Visit 0)\n10. Continuous supplemental oxygen use at rest greater than 2 L\u002Fmin\n11. Unable to swallow pills\n12. Taking a medication that has a major interaction with metformin, including acetazolamide (Diamox), cimetidine (Tagamet), dolutegravir, gatifloxacin, levoketoconazole, ranolazine, or carbonic anhydrase inhibitors. Occasional use of carbonic anhydrase inhibitors for travel is permitted.\n13. Current alcohol intake ≥ 15 drinks per week in men, ≥ 8 drinks per week in women or ≥ 5 drinks per occasion in men, ≥ 4 drinks per occasion in women\n14. Listed for transplant at the time of randomization",{"count":470,"type":20},800,[207],"This is a randomized, placebo-controlled trial of metformin in 400 participants with idiopathic pulmonary fibrosis (IPF) who are at high risk of adverse clinical outcomes based on a proteomic classifier. The primary objective is to assess the safety and efficacy of metformin compared to placebo in participants with IPF who are at high-risk for adverse clinical events.\n\nApproximately 800 participants with IPF will be screened. 400 participants who are at high risk for adverse clinical events (proteomic signature present) will be randomized into receiving metformin (n\\~200) or matching placebo (n\\~200). Participants that meet the eligibility criteria but do not have the proteomic signature (proteomic signature absent) will be contacted by phone at 12 and 24 months to review medical history.",[26],[26,30,475],"metformin","2026-04-08",{"date":478,"type":37},"2026-04-14",{"date":480,"type":20},"2026-08-01",{"date":482,"type":20},"2029-03-15",{"name":484,"class":129},"University of Massachusetts, Worcester",{"id":486,"slug":4,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":21,"phases":492,"briefSummary":493,"conditions":494,"keywords":495,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":502,"locationsCount":74},"100595713","NCT07036029","NAL ER IPF Respiratory Function and Safety Study","An Open Label, In-Clinic Study to Assess Respiratory Function and Safety of Escalating Doses of Nalbuphine Extended-Release Tablets (NAL ER) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)","Inclusion criteria:\n\n* Diagnosis of IPF as determined by a pulmonologist based on American Thoracic Society (ATS)\u002F European Respiratory Society (ERS) \u002F Japanese Respiratory Society (JRS) \u002F Asociación Latinoamericana de Tórax (ALAT) guidelines.\n* SpO2 ≥ 92%, taken after at least 5 minutes in a sitting position, undisturbed and non-stimulated - Saturation of Hemoglobin with Oxygen as measured by pulse oximetry.\n* FVC ≥ 40% of Global Lung Function Initiative (GLI) 2012 predicted values- Forced Vital Capacity, as determined by spirometry adhering to ATS\u002FERS guidelines.\n\nExclusion criteria:\n\n* Exacerbation of IPF in the last 3 months.\n* Positive results for coronavirus infection (COVID-19) at Day -2, prior to Admission to the clinical research unit (CRU).\n* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), or an forced expiratory volume in 1 second (FEV1)\u002Fforced vital capacity (FVC) \\\u003C0.8.\n* Currently using any overnight oxygen therapy at any level or delivered by any modality. Intermittent daytime oxygen use of any duration is allowed.\n* Diagnosis of sleep disordered breathing (e.g., sleep apnea).\n* Upper or lower respiratory tract infection within the 8 weeks prior to admission to the CRU.\n* Clinical history of aspiration pneumonitis.\n\nNote: Other inclusion\u002Fexclusion criteria mentioned in the protocol may apply.",{"count":320,"type":20},[154],"The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.",[26],[496],"nalbuphine",{"date":498,"type":37},"2026-04-09",{"date":500,"type":37},"2025-08-21",{"date":69,"type":20},{"name":240,"class":44},{"id":504,"slug":4,"hasResults":11,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":21,"phases":511,"briefSummary":512,"conditions":513,"keywords":514,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":523},"100610646","NCT07230288","Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis","A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects With Idiopathic Pulmonary Fibrosis","Inclusion Criteria:\n\n\\- Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) within 7 years prior to screening, confirmed by the investigator at screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained within 12 months of the screening visit and verification of usual interstitial pneumonia(UIP) or probable UIP.\n\nExclusion Criteria:\n\n* History of stroke within 6 months prior to screening\n* In the opinion of the investigator, other clinically significant pulmonary abnormalities\n* History of any malignancy up to 5 years prior screening visit, except for successfully treated nonmelanoma skin cancer or localized carcinoma in situ of the cervix.",{"count":510,"type":20},165,[23],"Idiopathic Pulmonary Fibrosis (IPF) is a rare, long-lasting lung disease that causes scarring of lung tissue, shortness of breath, and loss of lung function. IPF leads to significant loss of quality of life and shortened lifespan. This study is a platform study evaluating different types of treatments in patients with IPF. A platform study is a type of study that uses a single master protocol to evaluate different study treatments allowing for new study treatments or substudies to be added or closed over time. The main goals of the study are to evaluate the safety, tolerability (the degree to which the adverse symptoms can be handled by the patients during the study) and efficacy (how well study treatment works) of the study treatments, including ABBV-142 in Substudy 1 (SS1).\n\nABBV-142 is an investigational drug being developed for the treatment of IPF. In SS1, participants will be randomly assigned to one of the 2 groups to receive either ABBV-142 or a matching placebo. This study is \"double-blind\", meaning that neither the participants nor the study doctors know who is given which study treatment. Approximately 165 adult participants with IPF will be enrolled in approximately 125 sites across the world.\n\nParticipants will receive ABBV-142 or matching placebo for 52 weeks during the double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks in open-label treatment period. All participants will be followed for 120 days.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[26],[26],"2026-04-07",{"date":498,"type":37},{"date":518,"type":37},"2026-01-23",{"date":520,"type":20},"2029-09",{"name":522,"class":44},"AbbVie",6,{"id":525,"slug":4,"hasResults":11,"nctId":526,"briefTitle":527,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":11,"sex":16,"minAge":530,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":21,"phases":533,"briefSummary":534,"conditions":535,"keywords":543,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":556},"100515299","NCT05989698","Validation of the C-mo System - Cough Monitoring","C-mo_01","Inclusion Criteria:\n\n* Patients aged 2 years or older;\n* Patients with symptoms\u002Fcomplaints of cough;\n* Signed Informed Consent (age ≥ 18 years), signed Informed Consent from the parents\u002Flegal representative and the patient (16 and 17 years), or signed Informed Assent and Consent (5 years ≤ age ≤ 15 years).\n\nExclusion Criteria:\n\n* Presence of musculoskeletal (e.g., severe scoliosis), neurological (e.g., post stroke), cardiac (e.g., unstable angina), cognitive (e.g., dementia) changes, or other significant conditions that hinder the participants from collaborating in the collection of data.\n* Damaged\u002Fweakened skin at the C-mo wearable device's placement area (epigastric region).\n* Absence of Informed Consent and\u002For Assent, as applicable.","2 Years",{"count":532,"type":20},300,[176],"The goal of this clinical study is to validate C-mo System's ability to automatically detect and characterise cough, in patients over 2 years old with cough as a key or refractory symptom.\n\nThe main questions it aims to answer are:\n\n1. Can C-mo System detect cough events? (automatic cough detection)\n2. Can C-mo System characterise cough events? (calculation of cough intensity, identification of cough type and presence of wheeze in detected coughs)\n\nParticipants will be asked to:\n\n* Wear the C-mo Wearable device for 24 hours (1 day);\n* Complete a diary with relevant activities throughout the monitoring period;\n* Fill-out questionnaires related to coughing frequency and intensity, usability of the device, and impact of cough on quality of life.",[536,537,538,539,26,540,541,542],"Cough","Asthma","Chronic Obstructive Pulmonary Disease","Gastro Esophageal Reflux","Cough Frequency","Cough Severity","Coughing",[544,545,546,547],"Cough monitoring","Cough detection","Cough assessment","C-mo","2026-04-02",{"date":476,"type":37},{"date":551,"type":37},"2023-12-11",{"date":553,"type":20},"2026-09",{"name":555,"class":44},"Cough Monitoring Medical Solutions",8,{"id":558,"slug":4,"hasResults":11,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":21,"phases":566,"briefSummary":567,"conditions":568,"keywords":569,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":4},"100632689","NCT07516951","A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis","A Phase IIb, Multicentre, Randomised, Double Blind, Placebo Controlled, Three-arm Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability at Week 24 of 2 Doses of CHF10067 (Zampilimab), With an Optional 24-week Double Blind, Placebo Controlled Extension Phase in Participants With Idiopathic Pulmonary Fibrosis","ZAPPHIRE","Inclusion Criteria:\n\n* Informed consent: Participant's written informed consent obtained prior to any study-related procedure.\n* Sex and age: Male or female, of any race and ethnicity, aged ≥40 years with a life expectancy of at least 1 year at screening in the opinion of the Investigator.\n* Body weight ≥45 kg.\n* Diagnosis of IPF: Diagnosis as defined by the 2018 and 2022 American Thoracic Society\u002FEuropean Respiratory Society\u002FJapanese Respiratory Society\u002FLatin American Thoracic Society Guidelines for a maximum 8 years before screening. The most recent HRCT(High-resolution computed tomography) ≤6 months prior to screening, reviewed by central reading, should be used to confirm the diagnosis.\n* Lung function: Forced vital capacity (FVC) ≥45% of predicted normal value and a ratio of forced expiratory volume in the first second\u002FFVC ≥0.7 at screening.\n* Diffusing capacity of the lung for carbon monoxide (DLCO) corrected for haemoglobin ≥25% of predicted normal at screening.\n* Oxygen saturation measured by pulse oximetry (peripheral capillary oxygen saturation \\[SpO2\\]) \\>90% at rest when the maximum oxygen flow is 4 L\u002Fmin by standard nasal cannula or the equivalent oxygen delivery via reservoir nasal cannula (≤2 L\u002Fmin).\n\nExclusion Criteria:\n\n* Participant with a documented diagnosis of coeliac disease.\n* Low respiratory tract infection: Documented low respiratory tract infection in the last 4 weeks prior to screening or documented acute exacerbation of IPF (defined as acute worsening or development of dyspnoea typically \\\u003C1 month duration;\n* Lung cancer: Active diagnosis or history of lung cancer.\n* Emphysema: HRCT (refer to inclusion criterion #5 \\[Diagnosis of IPF\\]), reviewed by central reading, shows the presence of emphysema ≥20% or that the extent of emphysema is greater than the extent of fibrosis.\n* Organ transplantation: End-stage fibrotic disease expected to require organ transplantation within 6 months from screening.\n* Other medical conditions: Clinically relevant and uncontrolled pulmonary (including any non-IPF pulmonary diagnosis), cardiac, hepatic, gastrointestinal, renal, endocrine, metabolic, neurologic, psychiatric disorders, active or untreated latent tuberculosis\u002Ftuberculosis infection that may interfere with the participant's ability to complete this study according to the Investigator's judgement.\n* Any other comorbid non-IPF pulmonary condition that may impact FVC according to the Investigator's judgement. Emphysema is allowed, unless it meets the above exclusion criterion regarding emphysema.\n* Participant currently treated, or been treated with cytotoxic and immunosuppressant\u002Fmodulator drugs within 48 weeks prior to screening. Systemic (IV, intramuscular, or oral) corticosteroids prednisone- equivalent dose of \\>10 mg\u002Fday used for \\>10 days.\n* Hypersensitivity: Known intolerance and\u002For hypersensitivity to any of the excipients contained in the formulation or any other substance used in the study.\n* History of allergic or anaphylactic reaction to human, humanised, chimeric Igs (immunoglobulins), or murine monoclonal antibodies.",{"count":565,"type":20},240,[23],"The purpose of this study is to evaluate the efficacy, safety, and tolerability at Week 24 (Part A) of 2 doses of CHF10067 (zampilimab), with an optional 24-week double-blind, placebo-controlled extension phase (Part B) in participants with idiopathic pulmonary fibrosis.\n\nIt is a phase IIb, multicentre, randomised, double-blind, placebo-controlled, three-arm parallel-group study.\n\nA total of 240 participants with IPF (Idiomatic Pulmonary Fibrosis) will be randomised in approximately 150 investigational sites in North and Latin America, Europe, Asia, and Oceania. The optional extension phase (Part B) is only applicable to the European Union and Macedonia.",[26],[30],"2026-04-01",{"date":476,"type":37},{"date":573,"type":20},"2026-06-01",{"date":575,"type":20},"2028-02-12",{"name":577,"class":44},"Chiesi Farmaceutici S.p.A.",""]